Stay updated on ADI-PEG 20 with Gemcitabine/Docetaxel in Sarcomas/Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the ADI-PEG 20 with Gemcitabine/Docetaxel in Sarcomas/Lung Cancer Clinical Trial page.

Latest updates to the ADI-PEG 20 with Gemcitabine/Docetaxel in Sarcomas/Lung Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe study page now shows a 403 Forbidden error, replacing the study record content with an access-denied page. This prevents viewing the trial's details and related information.SummaryDifference20%

- Check43 days agoChange DetectedThe page's revision tag was updated from v3.6.5 to v3.6.6, indicating a minor update to the study page display.SummaryDifference0.1%

- Check57 days agoChange DetectedThe page now includes added institutional affiliations: Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, and Washington University School of Medicine. A new 'Helpful Links Provided by' header appears to indicate sources and related resources.SummaryDifference0.2%

- Check64 days agoChange DetectedTwo sponsor/institution credits were removed (Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine) and the 'Helpful Links Provided by' label was deleted; the revision tag was updated from v3.6.4 to v3.6.5.SummaryDifference0.2%

- Check79 days agoChange DetectedThe page now displays a new revision tag: Revision: v3.6.4, replacing the previous Revision: v3.6.3. This is a minor version update and does not alter study content or functionality.SummaryDifference0.0%

Stay in the know with updates to ADI-PEG 20 with Gemcitabine/Docetaxel in Sarcomas/Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ADI-PEG 20 with Gemcitabine/Docetaxel in Sarcomas/Lung Cancer Clinical Trial page.